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Immunosuppressive agents in childhood nephrotic syndrome: 85% of cases [2]. Overall, approximately 80 to 90% of
A meta-analysis of randomized trials. children respond to initial steroid treatment [2, 3], but
Background. Many children with steroid-sensitive nephrotic 76 to 93% relapse [2, 3]. Of the children who relapse,syndrome (SSNS) relapse frequently and receive immunosup-
approximately half relapse frequently (that is, more thanpressive agents. In this systematic review of randomized con-
2 relapses in 6 months or 4 or more relapses in any onetrolled trials (RCTs), the benefits and harms of these immuno-
suppressive agents are evaluated. year) or become steroid dependent (that is, relapse on
Methods. RCTs with outcome data at six months or more a reducing dose of prednisone or within two weeks of
that evaluated noncorticosteroid agents in relapsing SSNS were ceasing prednisone) [2–4]. These children are difficultincluded. A summary relative risk for relapse at 6 to 12 months
to manage in clinical practice because of steroid toxicity.was calculated using a random effects model.
Immunosuppressive agents are often used in childrenResults. Seventeen trials involving 631 children were identi-
fied. Cyclophosphamide [3 trials; relative risk (RR) 0.44, 95% with frequently relapsing NS for steroid-sparing effects.
confidence interval (CI), 0.26 to 0.73] and chlorambucil (2 trials; Cyclophosphamide and chorambucil were initially shown
RR 0.13, 95% CI, 0.03 to 0.57) significantly reduced the relapse
to be effective in prolonging remission in the 1960s [5],risk at 6 to 12 months compared with prednisone alone. In the
but their potential for carcinogenesis and infertility havesingle chlorambucil versus cyclophosphamide trial, there was
no observed difference in relapse risk at two years (RR 1.31, limited their use to one or two 8- to 12-week courses [6–8].
95% CI, 0.80 to 2.13). Cyclosporine was as effective as cyclo- Cyclosporine, levamisole, azathioprine, disodium cro-
phosphamide (1 trial; RR 1.07, 95% CI, 0.48 to 2.35) and moglycate, IgG immunoglobulin, and Chinese medicineschlorambucil (1 trial; RR 0.82, 95% CI, 0.44 to 1.53), but the
have also been used to treat relapsing NS [9–14]. Theeffect was not sustained when cyclosporine was ceased. During
variations in the recommendations for the type, dose,treatment, levamisole (3 trials; RR 0.60, 95% CI, 0.45 to 0.79)
was more effective than steroids alone, but the effect was not and duration of immunosuppressive agents have impor-
sustained. tant efficacy and side effect implications [15–17]. The
Conclusions. Cyclophosphamide, chorambucil, cyclosporine,
aim of this systematic review and meta-analysis of ran-and levamisole reduce the risk of relapse in children with re-
domized controlled trials (RCTs) was to assess the bene-lapsing SSNS compared with prednisone alone. Clinically im-
portant differences in efficacy among these agents are possible, fits and harms of the different immunosuppressive agents
and further comparative trials are still needed. Meanwhile, the used to treat children with frequently relapsing and ste-
choice between these agents depends on physician and patient roid dependent nephrotic syndrome.
preferences related to therapy duration and complication type
and frequency.
METHODS
Literature searchNephrotic syndrome (NS) has an incidence of approxi-
Randomized and quasi-RCTs were identified frommately 2 per 100,000 children [1], with minimal change
MEDLINE (1966 to March 1999), EMBASE (1988 todisease being the underlying histopathology in more than
March 1999), and the Cochrane Controlled Trials Regis-
ter (Cochrane Library Issue 1, 1999) without language re-
Key words: azathioprine, chlorambucil, cyclophosphamide, cyclosporine,
striction. The optimally sensitive strategies developed forlevamisole, prednisone, meta-analysis, steroid-sensitive nephrotic syn-
drome. the Cochrane Collaboration for the identification of
RCTs were used for MEDLINE [18] and EMBASEReceived for publication July 26, 2000
searches (abstract; Lefebvre et al, Proceedings of the 4thand in revised form November 22, 2000
Accepted for publication November 29, 2000 International Cochrane Colloquium A28, 1996). These
strategies were combined with the following medical sub-Ó 2001 by the International Society of Nephrology
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Table 1. Characteristics of the studies using cyclophosphamide in the treatment of relapsing nephrotic syndrome in childhood
Study Number
[Reference] enrolled Group 1 Group 2 Duration of treatment
Barratt [23] 30 CPA 3 mg/kg/day Prednisolone Group 1: 8 weeks and prednisolone
1970 prednisolone then tapered over 8 weeks
UK Group 2: Tapered over 8 weeks
Chiu [22] 23 CPA 75 mg/m2/day Prednisolone Group 1: 16 weeks
1973 prednisolone Group 2: 16 weeks
Canada
ISKDC [21] 53 CPA 5 mg/kg/day Prednisolone Group 1: 6 weeks (10 days of
1974 prednisolone prednisolone)
International Group 2: 26 weeks
Barratt [29] 32 CPA 3 mg/kg/day CPA 3 mg/kg/day Group 1: 2 weeks
1973 prednisolone prednisolone Group 2: 8 weeks
UK Both groups: tapered prednisolone
over 8 weeks
McCrory [31] 14 CPA 5 mg/kg/day CPA 2.5 mg/kg/day Group 1: 6 weeks
1973 prednisolone prednisolone Group 2: 12 weeks
USA
Ueda [30] 73 CPA 2 mg/kg/day CPA 2 mg/kg/day Group 1: 8 weeks
1990 prednisolone for prednisolone for Group 2: 12 weeks
Japan relapse only relapse only
APN [4] 50 CPA 2 mg/kg/day Chlorambucil 0.15 mg/ Group 1: 8 weeks
1982 prednisone kg/day prednisone Group 2: 8 weeks
Germany Both groups: Prednisone for
4 weeks
Ponticelli [11] 56 CPA 2.5 mg/kg/day Cyclosporine 6 mg/kg/ Group 1: 8 weeks
1993 prednisone for day prednisone for Group 2: 39 weeks, reducing over
Italy relapse only relapse only next 13 weeks
Abbreviations are: CPA, cyclophosphamide; ISKDC, International Study of Kidney Disease in Children; APN, Arbeitsgemeinschaft fu¨r Pa¨diatrische Nephrologie.
Table 2. Characteristics of the studies using chlorambucil, levamisole and azathioprine in relapsing nephrotic syndrome in childhood
Noncorticosteroid Number
agent(s) Study enrolled Group 1 Group 2
Chlorambucil Alatas 1978 [27] 20 Chlorambucil 0.3 mg/kg/day for Placebo for 8 weeks
Indonesia 8 weeks Prednisone for 8 weeks
Prednisone for 8 weeks
Chlorambucil Grupe 1976 [28] 21 Chlorambucil 0.1–0.2 mg/kg/day Prednisolone for 14–16 weeks
USA until wcc fell (6–12 weeks)
Prednisolone until wcc above
5000
Chlorambucil Baluarte 1978 [32] 21 Chlorambucil 0.2 mg/kg/day for Chlorambucil 0.2 mg/kg/day increasing by
USA 8 weeks about 0.1 mg/kg every 2 weeks for
Prednisolone until wcc above 6–11 weeks
4000 Prednisolone until wcc above 4000
Chlorambucil and Niaudet 1991 [33] 40 Chlorambucil 0.2 mg/kg/day for Cyclosporine 6 mg/kg/day for 12 weeks,
cyclosporine France 6 weeks tapered over 12 weeks
Prednisone for relapse Prednisone for relapse
Levamisole BAPN 1991 [12] 61 Levamisole 2.5 mg/kg on Placebo for 16 weeks
UK alternate days for 16 weeks Prednisolone for 8 weeks
Prednisolone for 8 weeks
Levamisole Dayal 1994 [25] 37 Levamisole 2–3 mg/kg twice a No treatment
India week for 52 weeks Prednisone for relapse
Prednisone for relapse
Levamisole Rashid 1996 [26] 40 Levamisole 2.5 mg/kg on Prednisolone for 26 weeks
Bangladesh alternate days for 26 weeks
Prednisolone alone for 26 weeks
Azathioprine ISKDC 1970 [9] 36 Azathioprine 60 mg/m2/day for Placebo for 26 weeks
International 26 weeks “Maintenance” prednisone
“Maintenance” prednisone
Azathioprine Barratt 1977 [27] 24 Azathioprine 2 mg/kg/day for Prednisolone alone for 8 weeks,
UK 8 weeks tapered over 8 weeks
Prednisolone for 8 weeks,
tapered over 8 weeks
Abbreviations are: wcc, white cell count; BAPN, British Association for Paediatric Nephrology; ISKDC, International Study of Kidney Disease in Children.
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ject heading and text word terms to limit the search to
nephrotic syndrome in children: nephrotic syndrome, ne-
phrosis, nephrosis-lipoid, and child. Reference lists of ne-
phrology textbooks, review articles, relevant trials, and
abstracts of scientific meetings were also searched. In-
vestigators with a known interest in this area were con-
tacted for information on any missed or unpublished trials.
Inclusion criteria
All randomized and quasi-randomized trials that eval-
uated noncorticosteroid agents in the treatment of re-
lapsing NS in children and had outcome data at a mini-
mum of six months were potentially eligible. Trials were
included if all participants were aged 3 months to 18
years or if the outcomes of children included in the trial
could be identified separately from those of the adults.
Trials were eligible if a nonsteroid agent was given in
comparison with placebo, steroids alone, no treatment,
or another nonsteroid agent. Enrolled participants were
required to be steroid responsive at the initial presenta-
tion and to have had at least one relapse. Trials enrolling
children with congenital NS, steroid resistant NS, or sec-
ondary NS were excluded.
The primary outcome measure was the proportion of
children who had relapsed at 6 to 12 and 13 to 24 months.
Secondary outcome measures sought were mean relapse
rate per patient per year, mean time to next relapse, and
adverse effects of therapy.
Data extraction and analysis
All titles and abstracts were screened independently
by two reviewers (A.D. and E.H.), and irrelevant studies
were discarded. The full text of the remaining studies
was assessed to determine if the inclusion criteria were
met. The included studies were all assessed for trial qual-
ity, by the same two reviewers, without blinding to author
or source. Any discrepancies in quality assessment were
resolved in discussion. The quality items assessed were
allocation concealment, intention to treat analysis, com-
pleteness of follow-up, and blinding of outcome [19].
Data were extracted onto standard preprepared forms.
Any required information not available in the article
was requested from the investigator(s) involved.
Statistical assessment
For dichotomous outcomes, the relative risks (RR)
with 95% confidence intervals (CIs) were calculated in
RevMan for individual studies [20], and the summary
statistics were calculated using a random effects model.
The random effects model takes into account the be-
tween-study variability as well as the within-study vari-
ability. A fixed-effect model was also used to test the
robustness of the model chosen and susceptibility to out-
liers. Statistical significance was tested for using the test
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Z statistic. To determine whether effect sizes were equiv-
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alent in all studies, heterogeneity between studies was compared different cyclophosphamide regimes (N 5
119) [29–31] and a further trial compared different chlor-tested for using Cochran’s Q statistic. The Q statistic has
a chi-square distribution and is determined from the sum ambucil regimes (N 5 21) [32]. There were single trials
comparing cyclosporine with cyclophosphamide (N 5of the weighted differences between the summary effect
measure and the measure of effect from each study. We 55) [11], cyclosporine with chlorambucil (N 5 40) [33],
and cyclophosphamide with chlorambucil (N 5 50) [4].hypothesized that certain between-study differences in
participants (frequently relapsing vs. steroid dependent), Prednisolone was used in all the trials either in combina-
tion with the trial agent or to treat relapses (Tables 1interventions (duration of treatment), and trial quality
may explain any observed heterogeneity of treatment and 2). No eligible RCTs comparing levamisole or aza-
thioprine with other noncorticosteroid agents or compar-effects. Examination of these possible between-study dif-
ferences was attempted by subgroup analysis. ing Chinese medicines, IgG immunoglobulin, or disodium
cromoglycate with corticosteroids or placebo were found.
RESULTS Study quality
Literature search The overall study quality was poor (Table 3). Only
five trials had adequate allocation concealment [4, 9, 11,Of the 832 titles and abstracts screened, 19 studies were
12, 22], and three trials were double blinded [9, 12, 27].identified by full-text review to be RCTs and to have
follow-up data of six months or more. There was no dis- None of the studies reported an intention to treat analy-
sis. Fourteen trials reported no loss to follow-up at sixagreement between the two reviewers regarding the inclu-
sion of trials. Two trials were subsequently excluded. One, months, and the other three trials had losses of less than
10% [23, 24, 30]. Four trials did not define relapse [25,assessing Chinese herbs, was excluded because both chil-
dren and adults were included and the pediatric data could 27, 32, 33], and the remaining studies used a variety of
definitions.not be separated [10]. The other, evaluating levamisole,
was in abstract form only, and the primary outcome mea-
Study outcomessure could not be determined from the data included
(abstract; Kirubakaran et al, Kidney Int 26:240, 1984). The Cyclophosphamide resulted in a decreased incidence
requested information to allow inclusion of these trials of relapse at 6 to 12 months (Fig. 1) [21–23] compared
could not be obtained from the authors. Seventeen trials with prednisolone alone (RR 0.44, 95% CI, 0.26 to 0.73).
were therefore included in this review. In 19 children followed up beyond 12 months, the RR
for relapse at 13 to 24 months was 0.13 (95% CI, 0.03
Study characteristics to 0.60) [22, 23]. A single trial showed that an eight-week
course of cyclophosphamide resulted in fewer childrenThe characteristics of the 17 trials are shown in Tables 1
and 2. A total of 631 children was assessed, and the relapsing within 12 months than a two-week course (RR
0.25, 95% CI, 0.07 to 0.92) [29]. There was no evidencehighest number of trials available for any one compari-
son was three: cyclophosphamide compared with steroid that prolonging the course from 8 weeks to 12 weeks
further reduced the number of children experiencing aalone (N 5 106 children) [21–23] and levamisole com-
pared with placebo, steroid alone, or no treatment (N 5 relapse (RR 1.04, 95% CI, 0.75 to 1.44) [30]. A third
trial showed that the same total dose of cyclophospha-138) [12, 24, 25]. Two trials compared azathioprine (N 5
60) [9, 26], and two trials compared chlorambucil with mide given over 6 weeks rather than 12 weeks did not
reduce the number of children who relapsed by 12placebo or steroid alone (N 5 41) [27, 28]. Three trials
b
Fig. 1. Meta-analyses of the relative risks (RR) and 95% confidence intervals (95% CIs) for relapse of NS by 4 to 12 months in 10 trials of
immunosuppressive agents compared with prednisone, placebo, or no treatment in children with relapsing NS. Results shown ordered by trial
weights. (A) Cyclophosphamide compared with prednisone. (B) Levamisole compared with prednisone or no treatment. (C ) Chlorambucil compared
with prednisone. (D) Azathioprine compared with prednisone. No heterogeneity was demonstrated using Cochran’s Q statistic (chi-square). The
test statistic Z indicates that cyclophosphamide, chlorambucil, and levamisole are significantly more effective in reducing the number of children
who relapse compared with prednisone or no treatment, while azathioprine is no more effective than prednisone alone. The numbers in the
experimental treatment column and control treatment column indicate the number of children (n) who suffered a relapse of nephrotic syndrome
(NS) compared with the total number of children (N) who were treated. The relative risks (RR) with 95% CIs are shown graphically and numerically
for individual studies and as a summary estimate (total) for the combined studies. The data were analyzed using the random effects model, which
takes into account the between-study variability as well as the within-study variability. Individual effect sizes (weight percentage) are weighted
according to the inverse of their variance. Cochran’s Q statistic, shown as chi-square analysis with degrees of freedom (d.f.), provides the formal
test of heterogeneity between studies. The test statistic Z is the formal test of significant effect. Studies are listed by first author and year of
publication. The abbreviations ISKDC (in meta-analyses of cyclophosphamide and azathioprine) and BAPN (in meta-analysis of levamisole) refer
to the International Study of Kidney Disease in Children and British Association for Paediatric Nephrology, respectively.
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months (RR 0.43, 95% CI, 0.02 to 9.00), but did increase cyclophosphamide was superior in maintaining remission
(RR 0.40, 95% CI, 0.22 to 0.73).the numbers experiencing side effects [31].
Side effects were reported in 14 trials; in the otherChlorambucil treatment also reduced the risk for re-
three trials, only the lack of serious infections and leuko-lapse at 12 months (RR 0.13, 95% CI, 0.03 to 0.57)
penia sufficient to cause cessation of the medication werecompared with placebo or prednisone alone (Fig. 1)
reported [23, 26, 29]. Both alkylating agents were associ-[27, 28]. The study comparing different chlorambucil re-
ated with leukopenia, thrombocytopenia, and infectionsgimes found no significant decrease in relapse rates using
(Table 4). Hair loss was reported uncommonly, and cysti-an increasing dose regime over the stable dose regime
tis was not seen with chlorambucil. There were two se-(RR 0.18, 95% CI, 0.01 to 3.41), but there was a 34%
vere infections reported with cyclophosphamide [4] andincrease in incidence of leucopenia and an 18% increase
three serious viral infections with chlorambucil, the latterin thrombocytopenia with the higher dose [32]. There
reported with the higher dose regime [32]. Gum hyper-was no significant difference between chlorambucil and
trophy and hirsutism were seen commonly with cyclo-cyclophosphamide treatment in the risk of relapse at 12
sporine (Table 4); elevated creatinine levels and hyper-and 24 months (RR at 24 months 1.31, 95% CI, 0.80 to
tension occurred in 9 and 4% children [11, 33]. With2.13; additional data provided by Professor J. Brodehl
levamisole, there was one case of gastrointestinal upsetfrom the trial by the Arbeitsgemeinschaft fu¨r Pa¨dia-
[12], and two of the three trials reported that no side effectstrische Nephrologie) [4]. Because both agents belong to
occurred [24, 25]. There was a single case of pulmonarythe same class of drug and because the single direct
embolus associated with azathioprine treatment [9].comparison did not show a statistically significant differ-
There were insufficient data to assess the mean relapseence in efficacy, the results of the five trials of alkylating
rate per patient per year and the mean time to nextagents versus prednisone alone were combined (RR 0.32,
relapse. There were insufficient trials of any treatment95% CI, 0.16 to 0.63). In the one trial that evaluated the
combination to allow any subgroup analyses.benefits of alkylating agents in children with frequently
relapsing steroid-sensitive NS (SSNS) compared with
children who were steroid dependent, chorambucil and DISCUSSION
cyclophosphamide were more effective in preventing re- Randomized controlled trials in children with relaps-
lapse in frequently relapsing children (RR at 24 months ing SSNS show that cyclophosphamide (2 to 3 mg/kg/day
0.34, 95% CI, 0.14 to 0.81) [4]. for 8 weeks), chlorambucil (0.2 mg/kg/day for 8 weeks),
Azathioprine did not cause a statistically significant cyclosporine (6 mg/kg/day), and levamisole (2.5 mg/kg
reduction in the number of children who relapsed at six on alternate days) substantially reduce the risk of relapse
months compared with placebo or steroid alone (RR compared with corticosteroid alone. These interventions
0.90, 95% CI, 0.59 to 1.38; Fig. 1) [9, 26]. Levamisole typically reduce the risk of relapse by approximately
was administered for 4 [12], 6 [25], or 12 [24] months. 50% for one to two years during and after a treatment
During administration, levamisole [12, 24, 25] was sig- course. This benefit is sustained beyond the on-treatment
nificantly more effective than prednisone alone (RR 0.60, period for the alkylating agents but only occurs during
95% CI, 0.45 to 0.79) with no significant heterogeneity treatment with levamisole and cyclosporine.
(Q 5 0.36; Fig. 1). There was no statistically significant Although these trial data show that immunosuppres-
benefit (RR 0.72, 95% CI, 0.47 to 1.11) over steroid alone sive treatment is better than no immunosuppressive
at 6 to 12 months when levamisole treatment had been treatment, between-agent trials have not demonstrated
ceased for 3 months in two trials. However, there was a clear benefit of one over any other in preventing NS
significant heterogeneity of effect (Q 5 7.80, P 5 0.02), recurrence. The relative efficacy of levamisole is not
which could be explained by the duration of treatment, known. Comparative trials of cyclophosphamide, chor-
suggesting that levamisole is effective during treatment, ambucil, and cyclosporine have been done, but because
but the effect is not sustained when treatment is ceased. of insufficient power, clinically important differences in
In the trial comparing cyclosporine with chlorambucil, treatment effects have not been excluded. For example,
cyclosporine was given for 24 weeks [33]. At six months, using the upper and lower bounds of the 95% CIs of the
both agents were equally effective in maintaining remis- RR estimate obtained from the single comparative trial
sion (RR 0.82, 95% CI, 0.44 to 1.53), but at 12 months, of chorambucil versus cyclophosphamide, chorambucil
cyclosporine was significantly less effective in maintaining could reduce the risk of recurrence by 20% or could
remission than chlorambucil (RR 0.47, 95% CI, 0.29 to double the risk of recurrence compared with cyclophos-
0.78). In the trial comparing cyclosporine with cyclophos- phamide. Similarly, compared with cyclophosphamide,
phamide, cyclosporine was given for 12 months, and the cyclosporine could reduce the risk of relapse by 50% or
risk for relapse at 9 months was similar for the two drugs could more than double the risk. Adequately powered
randomized comparative trials are required to determine(RR 1.07, 95% CI, 0.48 to 2.35) [11]. At 24 months,
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which of the four agents is most effective. Because cy-
closporine and cyclophosphamide are the two interven-
tions in most widespread use [15], a comparative trial of
these two medications would have the most applicability.
Assuming a 50% recurrence rate in the cyclosporine-
treated group, 130 patients would need to be recruited
to a RCT to detect a 50% statistically significant RR
reduction for relapse between the two agents. Until then,
choice between these agents must be based on other
noneffectiveness considerations, such as local availability
or licensing, costs, and physician and patient preferences
concerning duration of treatment and frequency and na-
ture of complications. By stratifying recruited patients
into frequent relapsers and steroid dependent, this trial
could also test the hypothesis that alkylating agents are
more effective in the frequent relapsing group and
cyclosporine is more effective in the steroid dependent
group, suggested by post hoc analysis of published trials
of alkylating agents [4] and uncontrolled studies of
cyclosporine [34, 35].
Our conclusions differ somewhat from recently pub-
lished guidelines that recommend eight weeks of chlor-
ambucil for frequently relapsing SSNS and 12 weeks of
cyclophosphamide for steroid dependent SSNS [15]. In
part, this may reflect the differences in information sources
used. For example, one study that has been influential
in shaping guidelines about cyclophosphamide use found
that 12 weeks of cyclophosphamide was more effective
than eight weeks in preventing relapse in children with
steroid dependent SSNS [36]. However, this study used
historical controls, which may be associated with an over-
estimation of the treatment effect [37]. In contrast, in a
RCT, increasing the duration of cyclophosphamide from
8 to 12 weeks did not improve efficacy [30].
What would the benefits and harms be of using an
immunosuppressive agent in a child with relapsing NS?
Cohort studies show that between 35 and 53% relapse
frequently at some time during their disease [2, 3]. Inter-
vention with immunosuppressive agents would only be
undertaken in this group of children whose risk for fur-
ther recurrences approaches 100% with corticosteroid
treatment alone. The meta-analysis shows that the RR
for relapse is 0.44 following cyclophosphamide, so the
risk for relapse is reduced from 100% to approximately
40%. Hence, on the benefit side of the equation, assum-
ing that all children will relapse, 60 fewer children would
relapse for every 100 children treated with cyclophospha-
mide [38]. On the harm side of the equation, for every
100 children treated with cyclophosphamide about 1
child will suffer a significant infection, 4 will develop
cystitis and 14 lose their hair. Children who relapse only
once during the first six months after the initial course
of prednisone treatment have only a 10% risk of becom-
ing a frequent relapser [3]. Thus, only 10 of 100 such
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children are considered at risk of relapsing frequently.
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dren would reduce the risk of relapse by 60%, only 6 of
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who relapse frequently.
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